Subgroup Analysis of the Green Study: Obinutuzumab and Bendamustine in Patients with Untreated CLL


Subgroup Analysis of the Green Study: Obinutuzumab and Bendamustine in Patients with Untreated CLL
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Jeff Sharman, MD (2/9/16)

Stilgenbauer S et al. Safety and efficacy of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia: Subgroup analysis of the Green study. Proc ASH 2015;Abstract 493.

Dr Sharman is Director of Research at the Willamette Valley Cancer Institute and Medical Director of Hematology Research at The US Oncology Network in Eugene, Oregon.